Catalyst

Slingshot members are tracking this event:

GlycoMimetics Set to Initiate Phase 1 Trials for GMI-1359 After Promising Data from Preclinical Trials

Source Link:
http://ir.glycomimetics.com/releasedetail.cfm?ReleaseID=945870

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GLYC
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details GlycoMimetics released preclinical trial data in December 2015 on GMI-1359 that aims to enhance the ability of chemotherapy to "target and improve survival from FLT3-ITD mutated acute myeloid leukemia (AML)".  Following this release, the Company expects to begin Phase 1 trials in 2H of 2016 following a filing for IND.
http://ir.glycomimet...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 06, 2016
Occurred Source:
http://ir.glycomimetics.com/releasedetail.cfm?ReleaseID=987893
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Gmi-1359, Phase 1 Clinical Study, Chemotherapy
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.